down arrow

Xiamen Amoytop Biotech Co. Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003RT3
  • SHG: 688278
CNY
51.40
-1.7 (-3.2%)

Sep 24

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Xiamen Amoytop Biotech Co. Ltd.

Why is Xiamen Amoytop Biotech Co. Ltd. ?

1
Poor Management Efficiency with a low ROCE of 40.89%
  • The company has been able to generate a Return on Capital Employed (avg) of 40.89% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of 35.97% and Operating profit at 51.22% over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 22.33% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 35.97% and Operating profit at 51.22% over the last 5 years
4
Negative results in Jun 26
  • INTEREST COVERAGE RATIO(Q) Lowest at 23,607.75
  • RAW MATERIAL COST(Y) Grown by 5.89% (YoY)
  • DEBT-EQUITY RATIO (HY) Highest at -5.75 %
5
With ROE of 27.84%, it has a fair valuation with a 5.95 Price to Book Value
  • Over the past year, while the stock has generated a return of -34.18%, its profits have risen by 14.8% ; the PEG ratio of the company is 1.4
  • At the current price, the company has a high dividend yield of 1.2
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Xiamen Amoytop Biotech Co. Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Xiamen Amoytop Biotech Co. Ltd. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Xiamen Amoytop Biotech Co. Ltd.
-36.85%
-0.03
35.64%
China Shanghai Composite
0.9%
0.22
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
35.97%
EBIT Growth (5y)
51.22%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
1.09
Tax Ratio
11.49%
Dividend Payout Ratio
24.51%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
44.33%
ROE (avg)
22.33%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
5.95
EV to EBIT
17.37
EV to EBITDA
15.79
EV to Capital Employed
7.64
EV to Sales
5.41
PEG Ratio
1.44
Dividend Yield
1.17%
ROCE (Latest)
43.98%
ROE (Latest)
27.84%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
NET SALES(HY)

At CNY 1,836.56 MM has Grown at 21.86%

CASH AND EQV(HY)

Highest at CNY 2,034.63 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.12 times

-17What is not working for the Company
INTEREST COVERAGE RATIO(Q)

Lowest at 23,607.75

RAW MATERIAL COST(Y)

Grown by 5.89% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -5.75 %

INTEREST(Q)

Highest at CNY 1.76 MM

Here's what is working for Xiamen Amoytop Biotech Co. Ltd.

Net Sales
At CNY 1,836.56 MM has Grown at 21.86%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Cash and Eqv
Highest at CNY 2,034.63 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio
Highest at 1.12 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Xiamen Amoytop Biotech Co. Ltd.

Interest Coverage Ratio
Lowest at 23,607.75 and Fallen
In each period in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest
At CNY 1.76 MM has Grown at 155.73%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest
Highest at CNY 1.76 MM
in the last five periods and Increased by 155.73% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio
Highest at -5.75 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 5.89% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading